Zhejiang Ausun Pharmaceutical Co Ltd
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, … Read more
Zhejiang Ausun Pharmaceutical Co Ltd (603229) - Total Liabilities
Latest total liabilities as of September 2025: CN¥713.05 Million CNY
Based on the latest financial reports, Zhejiang Ausun Pharmaceutical Co Ltd (603229) has total liabilities worth CN¥713.05 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Ausun Pharmaceutical Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Zhejiang Ausun Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhejiang Ausun Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Ausun Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Silex Systems Limited
OTCQX:SILXF
|
USA | $8.01 Million |
|
Zhejiang Noblelift Equip
SHG:603611
|
China | CN¥6.33 Billion |
|
Apacer Technology Inc
TW:8271
|
Taiwan | NT$2.55 Billion |
|
SEPLF
PINK:SEPLF
|
USA | $4.34 Billion |
|
KIRLOSKAR PNEUMATIC CO LTD
NSE:KIRLPNU
|
India | ₹5.21 Billion |
|
DFDS A/S
OTCGREY:DFDDF
|
USA | $26.16 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Zhejiang Ausun Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Ausun Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Ausun Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual total liabilities of Zhejiang Ausun Pharmaceutical Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥710.50 Million | -12.28% |
| 2023-12-31 | CN¥809.99 Million | -5.17% |
| 2022-12-31 | CN¥854.19 Million | +46.11% |
| 2021-12-31 | CN¥584.64 Million | +129.44% |
| 2020-12-31 | CN¥254.81 Million | +5.75% |
| 2019-12-31 | CN¥240.96 Million | +17.90% |
| 2018-12-31 | CN¥204.38 Million | +15.70% |
| 2017-12-31 | CN¥176.65 Million | -12.88% |
| 2016-12-31 | CN¥202.76 Million | -5.17% |
| 2015-12-31 | CN¥213.81 Million | +17.54% |
| 2014-12-31 | CN¥181.90 Million | +24.70% |
| 2013-12-31 | CN¥145.87 Million | +30.00% |
| 2012-12-31 | CN¥112.21 Million | -- |